Pediatric syrup containing Pelubi's active ingredient
"A new treatment option for childhood fever"

Daewon Pharmaceutical said on Nov. 16 that the Ministry of Food and Drug Safety had approved the Phase 2 clinical trial plan for DW5524, a pediatric syrup containing pelubiprofen, the active ingredient in Pelubi Tab, Korea's 12th domestically developed novel drug.


DW5524 is a suspension syrup containing pelubiprofen in liquid form, developed with the medication-taking needs of pediatric patients in mind. Daewon Pharmaceutical is pursuing pediatric formulation development and clinical research to expand its existing fever treatment portfolio for adults to children.

Daewon Pharmaceutical: "DW5524 Phase 2 Trial Plan Approved" View original image

The trial aims to enroll a total of 60 pediatric patients aged 2 to 12 with fever caused by acute upper respiratory tract infections. The primary endpoint is the reduction in body temperature four hours after administration. The trial will also assess the rate of temperature normalization, the time required for normalization, and adverse events.


The study is part of the Pediatric Disease Overcoming Research and Development Project, supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. Daewon Pharmaceutical is leading the research, with Chungbuk National University Hospital and Gyeongsang National University Hospital participating. The goal is to complete the Phase 2 pediatric trial and obtain approval for a subsequent Phase 3 trial plan.



A Daewon Pharmaceutical official said, "Building on our accumulated research experience, we will continue development to closely evaluate the antipyretic efficacy and safety in pediatric patients and provide a new treatment option for childhood fever."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing